Biotech

Breaking news and analysis on the biotech industry — covering drug development, clinical trials, IPOs, M&A, and the companies pushing biopharma forward.

Money present
Biotech

Rhythm doubles down on LG obesity license to as much as $855M

Increasing the potential windfall for LG to $855 million from the original $305 million, reflecting confidence in eventual sales of bivamelagon.
Michael Gibney Nov 3, 2026 9:32am
AbbVie booth at AACR 2026

AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’

Nov 3, 2026 8:38am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
Pfizer

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Nov 3, 2026 8:02am
video
Connected clinical research from fragmentation to progress

Connected clinical research: from fragmentation to progress

Brought to you by Medrio
Close-up of shredded document

Novartis scraps $800M BioArctic brain collab after barely a year

Nov 3, 2026 4:53am